Physician profile
Sam Davidoff
NPI 1003089673
$5,053.68
in general payments reported to CMS, 2019-2025
36 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $525 · 2021: $863 · 2022: $707 · 2023: $635 · 2024: $745 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,046.44 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $645.00 | 2019-2025 | Fasenra, Symbicort, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.36 | 2019-2025 | Ofev, Jardiance, Jascayd |
| Abbvie INC. | $310.17 | 2022-2024 | Avycaz, Teflaro, Dalvance |
| Mylan Specialty L.P. | $257.07 | 2019-2023 | Yupelri |
| Mallinckrodt Enterprises LLC | $247.80 | 2019 | |
| Insmed, INC. | $209.17 | 2019-2025 | Arikayce |
| Genzyme Corporation | $145.10 | 2021-2024 | |
| Olympus America INC. | $140.78 | 2021 | |
| Genentech USA, INC. | $140.70 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $138.79 | 2021-2022 | |
| Electromed, INC. | $118.98 | 2019-2025 | Smartvest |
| Axsome Therapeutics, INC. | $113.56 | 2025 | Sunosi |
| Grifols USA, LLC | $112.65 | 2022-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $100.89 | 2025 | Ohtuvayre |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $93.44 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $88.76 | 2019-2023 | Xarelto |
| Zoll Respicardia, INC. | $80.73 | 2024 | Remede System |
| Baxter Healthcare | $73.02 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Ani Pharmaceuticals, INC. | $68.93 | 2024 | Purified Cortrophin Gel |
| Amgen INC. | $62.15 | 2022-2025 | Tezspire |
| Pfizer INC. | $56.21 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.83 | 2024-2025 | Glassia |
| Inspire Medical Systems, INC. | $51.87 | 2023-2025 | Inspire |
| Shionogi INC | $41.47 | 2021-2023 | Fetroja |
| Apria Healthcare LLC | $35.25 | 2021 | |
| Sunovion Pharmaceuticals INC. | $35.20 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $32.56 | 2024 | |
| Gilead Sciences, INC. | $32.51 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $30.69 | 2021 | |
| Merck Sharp & Dohme LLC | $27.35 | 2020 | |
| Ethicon US, LLC | $22.91 | 2021 | |
| Paratek Pharmaceuticals, INC. | $21.83 | 2023 | Nuzyra |
| Philips North America LLC | $19.23 | 2023 | |
| Circassia INC. | $16.87 | 2020 | |
| Inogen, INC. | $16.41 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Davidoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.